COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy
Status:
Completed
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
According to the epidemiological situation worldwide and the number of vaccinations made,
there is little success in the fight against COVID-19. For many reasons, methylene blue is a
promising drug for an active treatment against SARS-CoV-2 infected patients. Since methylene
blue can work as a photosensitizer, photodynamic therapy as an antiviral treatment has great
potential in the treatment of COVID-19. This clinical study investigated the effectiveness of
SARS-CoV-2 infected people treatment using methylene blue and the following photodynamic
therapy on the base of the L.L. Levshin Institute of Cluster Oncology (Department of
Infectious Diseases №13) of I.M. Sechenov First Moscow State Medical University.
Phase:
Phase 1
Details
Lead Sponsor:
I.M. Sechenov First Moscow State Medical University
Collaborator:
Prokhorov General Physics Institute of the Russian Academy of Sciences (GPI RAS)